Related Experiment Video
Updated: Oct 22, 2025

An Experimental Model of Diet-Induced Metabolic Syndrome in Rabbit: Methodological Considerations, Development, and Assessment
Published on: April 20, 2018
Serum Sclerostin Is Associated with Peripheral and Central Systolic Blood Pressure in Pediatric Patients with Primary
Piotr Skrzypczyk1, Anna Ofiara1, Michał Szyszka2
1Department of Pediatrics and Nephrology, Medical University of Warsaw, 02-091 Warsaw, Poland.
Insights
Serum sclerostin levels did not differ between pediatric hypertension patients and controls, but were associated with blood pressure and height in children. This suggests a link between sclerostin and blood pressure regulation in pediatric hypertension.
Area of Science:
- Cardiovascular Research
- Pediatric Endocrinology
- Biochemistry
Background:
- The Wnt/beta-catenin pathway and its inhibitor, sclerostin, are implicated in arterial damage and cardiovascular outcomes.
- Understanding sclerostin's role in pediatric primary hypertension (PH) is crucial for assessing cardiovascular risk.
Purpose of the Study:
- To evaluate serum sclerostin concentration in children and adolescents with PH.
- To investigate the relationship between serum sclerostin and blood pressure, arterial damage, and calcium-phosphate metabolism in this population.
Main Methods:
- Serum sclerostin levels were measured in 60 pediatric PH patients and 20 healthy controls.
- Assessed calcium-phosphate metabolism, peripheral and central blood pressure (office and 24-h ambulatory), and arterial damage parameters.
- Utilized multivariate analysis to identify determinants of serum sclerostin.
Main Results:
- No significant difference in serum sclerostin was found between PH patients and controls.
- Sclerostin correlated positively with height Z-score, phosphate, and alkaline phosphatase.
- Sclerostin correlated negatively with age, peripheral systolic/mean blood pressure, and central systolic/mean blood pressure.
- Multivariate analysis identified height Z-score and systolic blood pressure Z-score as significant determinants of serum sclerostin.
Conclusions:
- Serum sclerostin levels are associated with blood pressure and height in the pediatric population.
- These findings suggest a potential role for sclerostin in blood pressure regulation within pediatric hypertension.
- Further research is warranted to elucidate the precise mechanisms involved.
Abstract:
Recent studies showed the significance of the canonical Wnt/beta-catenin pathway and its inhibitor-sclerostin, in the formation of arterial damage, cardiovascular morbidity, and mortality. The study aimed to assess serum sclerostin concentration and its relationship with blood pressure, arterial damage, and calcium-phosphate metabolism in children and adolescents with primary hypertension (PH). Serum sclerostin concentration (pmol/L) was evaluated in 60 pediatric patients with PH and 20 healthy children. In the study group, we also assessed calcium-phosphate metabolism, office peripheral and central blood pressure, 24 h ambulatory blood pressure, and parameters of arterial damage. Serum sclerostin did not differ significantly between patients with PH and the control group (36.6 ± 10.6 vs. 41.0 ± 11.9 (pmol/L), p = 0.119). In the whole study group, sclerostin concentration correlated positively with height Z-score, phosphate, and alkaline phosphatase, and negatively with age, peripheral systolic and mean blood pressure, and central systolic and mean blood pressure. In multivariate analysis, systolic blood pressure (SBP) and height expressed as Z-scores were the significant determinants of serum sclerostin in the studied children: height Z-score (β = 0.224, (95%CI, 0.017-0.430)), SBP Z-score (β = -0.216, (95%CI, -0.417 to -0.016)). In conclusion, our results suggest a significant association between sclerostin and blood pressure in the pediatric population.
Related Concept Videos
Hypertension and Regulation of Blood Pressure
Hypertension III: Clinical Manifestations and Diagnostic Studies
Hypertension I: Introduction
Special considerations while measuring blood pressure
Monitoring Both Arms:
Monitoring BP in both arms during the initial assessment is advisable, as the systolic value may differ by five to ten mm Hg between arms. For subsequent BP assessments, use the arm with the higher reading.
Hypertension II: Pathophysiology
Pre-Procedural Guidelines for Assessing Blood Pressure

